Alkermes expands sleep portfolio with acquisition worth up to $2.1B

Analysts called the proposed purchase of Avadel Pharmaceuticals a “clear” strategic fit for Alkermes, handing it an already marketed product for excessive daytime sleepiness.

Alector dementia drug, partnered with GSK, fails in key study

The negative readout led to a collapse in share price for Alector, which now plans to cut almost half of its workforce while refocusing and finding a new R&D leader.

The self-perform edge: Fast, reliable construction for life sciences facilities

Flagship bets again on AI with Expedition

The prolific company creator is staking $50 million on AI drug discovery for cancer and immune diseases, launching a biotech that already has a partnership with Pfizer.

Electra nabs $183M for its rare disease drug ambitions

The San Francisco-area biotech has a therapy in mid-stage testing for secondary hemophagocytic lymphohistiocytosis, a rare inflammatory condition.

Drugs from China are reshaping biotech. Track the licensing deals here.

At more than $11 billion, Takeda’s deal with Innovent Biologics has the second-largest total value of any China licensing pact this year, trailing only an alliance between GSK and Hengrui Pharma.

Novo’s main shareholder pushes out more than half of company’s board

The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, was too slow to react to obesity market shifts.